NCT06935994View on ClinicalTrials.gov

Aspirin for Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease

PHASE2RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

May 5, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2032

Conditions
Metabolic Dysfunction Associated Steatotic Liver Disease
Interventions
DRUG

Aspirin 81 mg Enteric Coated Tab - 1 tablet

Participants will be randomly assigned in a 1:1 ratio to receive daily low-dose (81mg) aspirin or a placebo

DRUG

Placebo

Participants will be randomly assigned in a 1:1 ratio to receive daily low-dose (81mg) aspirin or a placebo

Trial Locations (1)

40705

RECRUITING

Taichung Veterans General Hospital, Taichung

All Listed Sponsors
lead

Taichung Veterans General Hospital

OTHER